Antibody–Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo-Reference-Cited by-同舟云学术

Antibody–Drug Conjugates Derived from Cytotoxic seco-CBI-Dimer Payloads Are Highly Efficacious in Xenograft Models and Form Protein Adducts In Vivo

Published:2019-04-10 Issue:5 Volume:30 Page:1356-1370
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Su Dian¹^ORCID,Chen Jinhua²,Cosino Ely¹,dela Cruz-Chuh Josefa¹,Davis Helen¹,Del Rosario Geoffrey¹,Figueroa Isabel¹,Goon Leanne¹,He Jintang¹^ORCID,Kamath Amrita V.¹,Kaur Surinder¹,Kozak Katherine R.¹,Lau Jeffrey¹,Lee Donna¹,Lee M. Violet¹,Leipold Douglas¹,Liu Luna¹,Liu Peter¹,Lu Guo-Liang³^ORCID,Nelson Chris¹,Ng Carl¹,Pillow Thomas H.¹,Polakis Paul¹,Polson Andrew G.¹,Rowntree Rebecca K.¹,Saad Ola¹,Safina Brian¹,Stagg Nicola J.¹,Tercel Moana³^ORCID,Vandlen Richard¹^ORCID,Vollmar Breanna S.¹^ORCID,Wai John²,Wang Tao²,Wei BinQing¹,Xu Keyang¹,Xue Juanjuan²,Xu Zijin²,Yan Gang²,Yao Hui²,Yu Shang-Fan¹,Zhang Donglu¹,Zhong Fiona¹,Dragovich Peter S.¹^ORCID

Affiliation:

1. Genentech Inc., 1 DNA Way, South San Francisco, California 94080, United States

2. WuXi AppTec Co., Ltd., 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai 200131, China

3. Auckland Cancer Society Research Centre, Faculty of Medical and Health Sciences, The University of Auckland, Private Bag 92019, Auckland 1142, New Zealand

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.9b00133

Reference59 articles.

1. Strategies and challenges for the next generation of antibody–drug conjugates

2. Antibody-Drug Conjugates: An Emerging Concept in Cancer Therapy

3. The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

4. Ado-trastuzumab Emtansine (T-DM1): An Antibody–Drug Conjugate (ADC) for HER2-Positive Breast Cancer

5. Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Covalent Modification of Proteins by Osthole Reactive Metabolites using Proteomic Approaches;Current Drug Metabolism;2023-08

2. A comprehensive review of key factors affecting the efficacy of antibody drug conjugate;Biomedicine & Pharmacotherapy;2023-05

3. Degrader-antibody conjugates;Chemical Society Reviews;2022

4. Multiplexed Quantitative Analysis of Antibody–Drug Conjugates with Labile CBI-Dimer Payloads In Vivo Using Immunoaffinity LC-MS/MS;Analytical Chemistry;2021-12-27

5. Antibody-Drug Conjugate PCMC1D3-Duocarmycin SA as a Novel Therapeutic Entity for Targeted Treatment of Cancers Aberrantly Expressing MET Receptor Tyrosine Kinase;Current Cancer Drug Targets;2021-12-22